Core Viewpoint - Ganli Pharmaceutical (603087.SH) announced that its wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the investigational drug GLR1044 injection, a biosimilar to Dupilumab, aimed at treating moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription drugs [1]. Group 1 - The approval notice for GLR1044 injection has the acceptance number CXSL2500849 and the notice number 2025LP03316 [1]. - GLR1044 injection is a biosimilar of Dupilumab, which is used for treating atopic dermatitis [1].

Core Insights - The eighth China International Import Expo (CIIE) concluded successfully, showcasing a significant shift of exhibitors towards becoming partners in exploring the Chinese market [1][4] - The expo generated substantial procurement intentions and contracts, highlighting deepening connections between China and global enterprises [1][2] Group 1: Event Overview - The CIIE featured over 36.7 million square meters of exhibition space with participation from 4,108 companies across 138 countries, marking record highs in both area and number of exhibitors [2] - The intended transaction amount for this year's expo reached $83.49 billion, a 4.4% increase from the previous year [2] - A total of 461 new products, technologies, and services were launched, including 201 global debuts and 195 Chinese debuts, with a notable focus on artificial intelligence and robotics [2] Group 2: Economic Impact - China has maintained its position as the world's largest goods trader for eight consecutive years and is the second-largest import market globally for 16 years [2][3] - In the first three quarters of 2025, China's total goods trade reached 33.61 trillion yuan, with imports growing by 4.7% in the third quarter [3] - The country has actively expanded its import market, adding 135 new agricultural products from 50 countries and regions [3] Group 3: Long-term Participation and Local Integration - 180 companies have participated in all eight editions of the CIIE, demonstrating their commitment to the Chinese market [5][6] - Companies like GE Healthcare and Sanofi have successfully transitioned products from exhibition to clinical application, showcasing the effectiveness of the expo in fostering local production [5][6] - The CIIE has become a platform for innovation and localization, with companies like Honeywell and Wyeth Nutrition emphasizing their focus on local R&D and market integration [7] Group 4: Future Prospects - Preparations for the ninth CIIE are already underway, with nearly 100 foreign companies securing exhibition space, indicating continued trust in the Chinese market [8]

Core Viewpoint - The announcement indicates that the subsidiary of the company, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, a biosimilar to Dupixent, aimed at treating moderate to severe atopic dermatitis in adults [1] Group 1 - The clinical trial approval for Dupilumab injection is a significant step for the company in the biopharmaceutical sector [1] - Dupilumab injection is a fully human monoclonal antibody targeting IL-4Rα, which positions it as a competitive product in the treatment of atopic dermatitis [1] - The drug is intended to serve as a biosimilar to Dupixent, which is already established in the market [1]